156. Rett syndrome Clinical trials / Disease details
Clinical trials : 40 / Drugs : 53 - (DrugBank : 19) / Drug target genes : 77 - Drug target pathways : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-005021-76-IT (EUCTR) | 31/01/2013 | 11/12/2012 | Phase 2A clinical trial conducted on children affected by Rett syndrome and who are casually administered with the experimental treatment, EPI-743, compared versus the se of placebo. | A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children with Rett Syndrome | Rett Syndrome MedDRA version: 14.1;Level: HLGT;Classification code 10021605;Term: Inborn errors of metabolism;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: EPI-743 Product Code: NA Other descriptive name: Alpha-tocotrienol quinone | EDISON PHARMACEUTICALS INC. | NULL | Not Recruiting | Female: yes Male: no | Phase 2 | Italy |